Relationship Between Human Atrial Natriuretic Peptide and Tricuspid Valve Annular Dilatation in Patients With Atrial Fibrillation
Echocardiography · 2025
DOI: 10.1111/echo.70193 ↗At a glance
Journal article in Echocardiography, 2025. Written by Kanako Izumi and 10 co-authors. Institution: Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. Major MEDLINE topics: Atrial Fibrillation, Tricuspid Valve, Atrial Natriuretic Factor, Echocardiography, Three-Dimensional. Cited 3 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Japan Society for the Promotion of Science.
Abstract (original language)
Background
Atrial fibrillation (AF) may cause right‐sided heart remodeling such as tricuspid valve annular (TVA) dilatation, leading to atrial functional tricuspid regurgitation with prognostic impact. Not all AF patients develop TVA dilatation; therefore, predicting its occurrence is challenging. This study aimed to investigate human atrial natriuretic peptide (hANP) as a potential diagnostic marker of TVA dilatation in AF patients.
Methods
A total of 346 patients with lone AF (222 paroxysmal AF [paroxAF], 124 persistent AF [persAF]) who underwent 2‐dimensional (2D) transthoracic and 3‐dimensional (3D) transesophageal echocardiography (TEE) were retrospectively reviewed. This cohort was considered to have normal tricuspid valve geometry screening by 3D‐TEE and having no left‐side heart disease, pulmonary hypertension, and right ventricular dysfunction. We evaluated the association of plasma hANP concentration with AF‐related right‐sided heart remodeling including right atrial (RA) dilatation and TVA dilatation.
Results
Plasma hANP levels showed a correlation with RA area index in the paroAF group ( r = 0.27, p < 0.001) but not in the persAF group. In contrast, as for association with 3D TVA area, plasma hANP levels demonstrated an inverse correlation with 3D TVA area ( r = −0.25, p = 0.005) in the persAF group, especially with TVA diameter in the anterior‐posterior direction, but not in the paroAF group. Multivariate analysis revealed that reduced hANP levels were independently associated with TVA dilatation (per 1 increase in Log 10 hANP, β : −0.17 [95% CI: −306.7 to −7.59]; p = 0.04).
Conclusion
Declining plasma hANP levels may serve as a marker for diagnosing TVA dilatation in persAF patients, highlighting its potential role in assessing AF‐related structural changes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
ORCID profiles: Hiroto Utsunomiya
Funding
- Japan Society for the Promotion of Science
Cite
APA
Izumi, K., Utsunomiya, H., Tohgi, K., Takeuchi, M., Hamada, A., Hyodo, Y., Tsuchiya, A., Mogami, A., Ueda, Y., Takahari, K., & Nakano, Y. (2025). Relationship Between Human Atrial Natriuretic Peptide and Tricuspid Valve Annular Dilatation in Patients With Atrial Fibrillation. Echocardiography. https://doi.org/10.1111/echo.70193
Vancouver
Izumi K, Utsunomiya H, Tohgi K, Takeuchi M, Hamada A, Hyodo Y, et al. Relationship Between Human Atrial Natriuretic Peptide and Tricuspid Valve Annular Dilatation in Patients With Atrial Fibrillation. Echocardiography. 2025. doi:10.1111/echo.70193
BibTeX
@article{Izumi2025,
author = {Izumi, Kanako and Utsunomiya, Hiroto and Tohgi, Kiyotaka and Takeuchi, Makoto and Hamada, Ayano and Hyodo, Yohei and Tsuchiya, Akane and Mogami, Atsuo and Ueda, Yusuke and Takahari, Kosuke and Nakano, Yukiko},
title = {Relationship Between Human Atrial Natriuretic Peptide and Tricuspid Valve Annular Dilatation in Patients With Atrial Fibrillation},
journal = {Echocardiography},
year = {2025},
doi = {10.1111/echo.70193}
}
EUVIMED